Kolon TissueGene (950160) Q3 2024 earnings summary

Executive summary

• Focused on cell and gene therapy platform TG-C, targeting osteoarthritis and related musculoskeletal diseases, with U.S. Phase 3 clinical trials completed for knee OA and pipeline expansion into hip OA and degenerative disc disease.

• Operates two segments: Bio (TG-C) and Health & Beauty distribution, with the majority of revenue from the Bio segment via technology export and raw material supply.

• Maintains strong R&D orientation, with significant investment in clinical development and a robust patent portfolio.

Financial highlights

• 2024 Q3 revenue: $3.17M (Bio: $2.53M, Distribution: $0.64M); operating loss: $(11.47)M.

• Net loss for 2024 Q3: $(11.09)M; basic/diluted EPS: $(0.73).

• Cash and equivalents at Q3-end: $21.8M; total assets: $146.2M; equity: $112.8M.

• R&D expenses YTD: $45.4M (1,431% of sales), reflecting heavy investment in clinical trials.

• No dividends declared; ongoing capital raises through equity and convertible bonds.

Outlook and guidance

• Plans to submit BLA to FDA after 2-year follow-up of Phase 3 knee OA trial participants.

• Pipeline expansion into hip OA (Phase 2 approved) and degenerative disc disease (Phase 1 approved); further indications under consideration.

• Expects continued high R&D spending and negative operating margins until commercialization.